Fabrication of graphene oxide-β-cyclodextrin nanoparticle releasing doxorubicin and topotecan for combination chemotherapy. (16th October 2015)

• Record Type: Journal Article
• Authors: Wu, H.; Peng, J.; Wang, S.; Xie, B.; Lei, L.; Zhao, D.; Nie, H.
• Is Part Of: Materials technology. Volume 30:Supplement B4(2015)
• Page Start: 242
• Page End: 249
• Publication Date: 2015-10-16
• Subjects: Graphene oxide -- β-cyclodextrin -- Controlled delivery -- Combination chemotherapy; Materials -- Periodicals; Materials science -- Periodicals; Materials -- Technological innovations -- Periodicals; 620.1105
• DOI: 10.1179/17535557B15Y.000000004
• Languages: English
• ISSNs: 1066-7857

Abstract

Abstract : Controlled delivery of dual chemical drugs may increase the efficiency of chemotherapy. In this work, doxorubicin (DOX) was bound to adamantanecarboxylic acid (AD-COOH) through covalent linkage to form AD-DOX, while graphene oxide (GO) was modified by ethylenediamino-β-cyclodextrin (EDA-CD) to form graphene oxide-β-cyclodextrin (GO-CD), then GO-CD was assembled with as-produced AD-DOX via host–guest interaction. In contrast to the conjugation of DOX via covalent linkage, topotecan (TPT) was loaded onto GO through π–π stacking interaction. It was found that TPT/GO-CD/AD-DOX nanoparticles synchronised the delivery of DOX and TPT, and pH value played a critical role in determining the release profiles of dual drugs. Moreover, in vitro cellular investigations proved that TPT/GO-CD/AD-DOX nanoparticles were superior to free drugs and single-drug loaded nanoparticles in inhibiting the growth of HeLa cells. As a kind of injectable biomaterials, this controlled drug delivery device offers a solution to simultaneous delivery of dual chemical drugs in cancer lesion positions. Authors expect that this platform can be exploited for controlled delivery of various drug combinations for combination chemotherapy.